Skip to content
Featured on Startup Fame

Peptris Technologies secures ₹70 crore Series A for AI-led preclinical drug discovery

Peptris Technologies, a Bengaluru-based startup using AI to accelerate preclinical drug discovery, has raised ₹70 crore in a Series A funding round. The company focuses on rare diseases, inflammation, oncology, and women's health, and has licensed its lead asset to Revio Therapeutics.

Editor, Lazyfounder

Published Updated 3 min read
Peptris Technologies secures ₹70 crore Series A for AI-led preclinical drug discovery

What Peptris does

Peptris Technologies uses AI to generate and predict the properties of novel molecular structures for drug development. Its platform aims to identify promising candidates and weed out those likely to fail due to toxicity, instability, or inefficacy before costly laboratory work begins.

The company also works on repurposing existing compounds for new therapeutic uses and reviving those that failed for reasons unrelated to their potential in other indications. This approach reduces development time and leverages existing safety data.

Its lead asset, PEPR-124, was discovered using its AI platform and licensed exclusively to Revio Therapeutics for development in Duchenne muscular dystrophy. The company describes PEPR-124 as "Phase 2-ready" and "mutation-agnostic," meaning it could treat patients regardless of their specific genetic mutation.

Funding details and plans

Peptris raised ₹70 crore ($7.7 million) in a Series A round announced in February 2026. The round was co-led by IAN Alpha Fund and Speciale Invest, with participation from Tenacity Ventures and BYT Ventures. Speciale Invest had previously led a pre-seed round of about ₹8 crore ($1 million) in December 2023.

The funds will be used to deepen the company’s technology, expand its drug pipeline, push programmes toward clinical readiness, and build partnerships in North America and Europe. Peptris also plans to strengthen its scientific and technology teams.

Therapeutic focus and competition

Peptris targets rare diseases, inflammation, oncology, and women’s health—areas where research funding has historically been limited, particularly for women’s health. Its approach aims to address gaps in drug development for underserved conditions.

The company competes with other Indian AI-driven drug discovery startups, including ImmunitoAI, Boltzmann, and Aarogya AI. These firms are also leveraging AI to accelerate preclinical research, though none of Peptris’ compounds have yet completed clinical trials.

PEPR-124 has received orphan drug designation from the US Food and Drug Administration (FDA). This status provides development incentives for treatments targeting rare conditions but does not indicate efficacy or approval.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Peptris’ funding and progress signal growing investor confidence in AI-driven drug discovery, particularly in India’s emerging biotech sector. For founders and operators, this highlights a few key points:

  1. Market validation for AI in drug discovery: The fact that Peptris has secured significant funding and partnerships—including licensing its lead asset—suggests that AI is gaining traction as a viable tool for preclinical research. This could encourage other startups to explore similar models, especially in therapeutic areas with limited funding, like rare diseases and women’s health.

  2. Repurposing as a cost-effective strategy: Peptris’ focus on repurposing existing compounds demonstrates a pragmatic approach to reducing time and costs in drug development. For founders in biotech, this strategy could be worth considering, particularly in markets with constrained budgets or where speed to clinic is critical.

  3. Regulatory incentives for rare diseases: The FDA’s orphan drug designation for PEPR-124 underscores the potential advantages of targeting rare conditions. Startups in this space may benefit from regulatory incentives, which can help offset development costs and attract investors.

  4. Competitive landscape: The rise of AI-driven drug discovery startups in India—like ImmunitoAI, Boltzmann, and Aarogya AI—means founders in this space need to differentiate not just in technology but also in therapeutic focus, partnerships, and execution. Peptris’ licensing deal with Revio Therapeutics sets a benchmark for what early success might look like.

Sources

  1. yourstory.com
    Peptris is using AI to find drug candidates to shorten the time it takes for laboratory validation

This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.

About the author

Editor, Lazyfounder

Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.

More stories by Tarun Mottlia

Get the LazyFounder Brief

Startup, funding and AI news in a five-minute read. Join the early-access list.

Lazy Founder - Powered by Blogy.in

Contact us

Have a story tip, correction or partnership idea?

Write to us at tarun.kumar@blogy.in or talk to the founder directly. We read every message.

Contact us